
Apoptosis after traumatic human spinal cord injury

Evelyne Emery, M.D., Philipp Aldana, M.D., Mary Bartlett Bunge, Ph.D., William Puckett, Anu Srinivasan, Ph.D., Robert W. Keane, Ph.D., John Bethea, Ph.D., and Allan D. O. Levi, M.D., Ph.D., F.R.C.S.(C)

Department of Neurological Surgery and the Miami Project to Cure Paralysis, and Department of Physiology and Biophysics, University of Miami School of Medicine, Miami, Florida; and IDUN Pharmaceuticals, Inc., La Jolla, California

Object. Apoptosis is a form of programmed cell death seen in a variety of developmental and disease states, including traumatic injuries. The main objective of this study was to determine whether apoptosis is observed after human spinal cord injury (SCI). The spatial and temporal expression of apoptotic cells as well as the nature of the cells involved in programmed cell death were also investigated.

Methods. The authors examined the spinal cords of 15 patients who died between 3 hours and 2 months after a traumatic SCI. Apoptotic cells were found at the edges of the lesion epicenter and in the adjacent white matter, particularly in the ascending tracts, by using histological (cresyl violet, hematoxylin and eosin) and nuclear staining (Hoechst 33342). The suspected presence of apoptotic cells was supported by staining with the terminal deoxynucleotidyl transferase-mediated biotinylated-deoxyuridinetriphosphate nick-end labeling technique and confirmed by immunostaining for the processed form of caspase-3 (CPP-32), a member of the interleukin-1-beta-converting enzyme/*Caenorhabditis elegans* D 3 family of proteases that plays an essential role in programmed cell death. Apoptosis in this series of human SCIs was a prominent pathological finding in 14 of the 15 spinal cords examined when compared with five uninjured control spinal cords. To determine the type of cells undergoing apoptosis, the authors immunostained specimens with a variety of antibodies, including glial fibrillary acidic protein, 2',3'-cyclic nucleotide 3'-phosphohydrolase (CNPase), and CD45/68. Oligodendrocytes stained with CNPase and a number of apoptotic nuclei colocalized with positive staining for this antibody.

Conclusions. These results support the hypothesis that apoptosis occurs in human SCIs and is accompanied by the activation of CPP-32 of the cysteine protease family. This mechanism of cell death contributes to the secondary injury processes seen after human SCI and may have important clinical implications for the further development of protease inhibitors to prevent programmed cell death.

Key Words * apoptosis * human spinal cord injury * caspase-3

Apoptosis is an important biological process in eukaryotes in which individual cells die by activating an intrinsic suicide mechanism. Apoptosis is distinguished from necrotic cell death by morphological and biochemical criteria. Apoptosis is an active process of cell destruction characterized by cell shrinkage, chromatin aggregation with genomic fragmentation, and nuclear pyknosis.[27,31] In contrast, necrosis is characterized by passive cell swelling, intense mitochondrial damage with rapid energy loss, and disruption

of internal homeostasis. Necrosis leads to membrane lysis and release of intracellular constituents that evoke an inflammatory reaction.[10,37,43]

Apoptosis has long been known to occur as a form of neuronal cell death during embryonic development[22,25] and has been observed more recently following damage to the nervous system caused by ischemia, neurodegenerative conditions, inflammatory diseases, and traumatic injuries.[3,6,22,24,41,44,46,50,54] Caspases are a family of cysteine proteases that play an important role in the effector phase of apoptosis. Caspase-3 (CPP-32), in particular, has been shown to be important in neural development and injury: germline deletions of this protease led to severe neurological defects in mice.[24] The contribution of CPP-32 activity and apoptosis to neuronal cell death after traumatic brain injury[54] and experimental transient ischemia[24,41] have been reported. In both injury paradigms, the use of caspase inhibitors not only reduced the extent of apoptosis, but also resulted in functional behavioral improvement in the animals.

The presence of apoptosis in spinal cord injury (SCI) following a contusion has been reported recently in rats and monkeys.[11,32,35,36] In these studies, it was shown that apoptosis contributed to the tissue damage seen after SCI. Apoptotic cell death was observed in both neurons and oligodendrocytes[11,36] and was prominent in the white matter, in which wallerian degeneration was simultaneously observed. A time course analysis in rats[36] revealed that apoptosis occurred as early as 4 hours postinjury and cell deaths could be seen in decreasing numbers as late as 3 weeks after SCI.

We initiated this study to determine by examining the spinal cords of patients who died between 3 hours and 2 months postinjury whether apoptosis is an important factor after human SCI. Apoptosis in these 15 patients was assessed using multiple criteria, including nuclear morphology, chromatin staining techniques, and immunostaining for a processed form of CPP-32. We also determined the spatial and temporal expression of apoptotic cells and the nature of the cells involved in programmed cell death.

CLINICAL MATERIAL AND METHODS

Patient Population

This study was based on postmortem examination of spinal cord tissue from five control patients without SCI and 15 patients who died at different time points after an SCI. Fifteen specimens were obtained from the Miami Project's Human Spinal Cord Injury Bank, which contains more than 100 injured human spinal cords. The cases were selected based on the short interval between SCI and death (0-2 months) and the availability of tissue above and below the lesion site.

Preparation of Specimens

The spinal cords had been removed at autopsy, usually within 16 hours after death. They were then fixed in 10% neutral buffered formalin for a minimum of 15 days, after which they were stored in 0.1 M phosphate buffer at 4°C. Selected tissue blocks were taken at the epicenter and at three consecutive root levels above and below the injury. Samples from each of these regions were dehydrated, embedded in paraffin, and cut in 7- μ m-thick cross-sections.

Sections were stained with hematoxylin and eosin and cresyl violet (15 samples), terminal deoxynucleotidyl transferase (TdT)-mediated biotinylated-deoxyuridinetriphosphate nick-end labeling ([TUNEL], five samples), Hoechst 33342 (four samples), and immunostained with CM1, an antibody that preferentially recognizes the processed form of CPP-32 (10 samples). Sections from control spines (five samples) were stained with cresyl violet and immunostained with the CM1 antibody. Wallerian degeneration in white matter tracts was assessed using a silver stain for axons (Sevier-Munger) and a myelin stain (solochrome-cyanine)

on adjacent sections. Regions undergoing wallerian degeneration contained swollen, fragmented, or absent axons in the same areas in which myelin was distorted or collapsed. Wallerian degeneration was quantified in the white matter above and below the lesion according to four levels of severity: subtle, mild, moderate, and severe.

Staining With the TUNEL Technique

To determine whether DNA fragmentation characteristic of apoptosis occurs, we stained spinal cord tissue by using the in situ TUNEL technique.[20] Spinal cord sections were deparaffinized in xylene for 5 minutes and then rehydrated sequentially in 100%, 95%, 75%, and 50% ethanol. The sections were incubated with 50 µg/ml proteinase K for 5 minutes to strip off nuclear proteins. The TUNEL staining was completed using the apoptosis in situ kit according to the manufacturer's instructions.

Briefly, sections were immersed in equilibration buffer for 10 minutes and then incubated with TdT and deoxyuridinetriphosphate-fluorescein isothiocyanate in a humidified chamber at 37°C for 1 hour. The sections were washed with 0.1 M phosphate-buffered saline (PBS) at pH 7.4 and counterstained with propidium iodide (a nuclear stain) for 10 minutes. As a positive control we pretreated slides with DNAase to produce TUNEL-positive staining of all nuclei, and the negative controls were incubated without TdT enzyme. Sections were examined and photographed using fluorescence microscopy.

Hoechst 33342 Staining

Spinal cord sections were deparaffinized with xylene for 5 minutes, rehydrated, and rinsed with 0.1 M PBS. The sections were stained with one drop of glycerol/PBS solution containing 5 µl Hoechst 33342 dye (5.6 mg in 10 ml PBS).

Immunostaining for Processed Form of Caspase-3 With the CM-1 Antibody

Spinal cord sections were deparaffinized as described earlier, rinsed in 0.01 M PBS and treated for 30 minutes with 3% H₂O₂ in 10% methanol. The sections were blocked for 1 hour in 5% normal goat serum with 0.1 M PBS and 0.1% Triton X-100. The primary antibody CM-1 (0.012 µg/ml) was applied and the preparations were left overnight. The following morning, the sections were fixed for 10 minutes in 0.01 M PBS containing 0.1% glutaraldehyde. The sections were incubated for 1 hour with a biotinylated secondary antibody, followed by a 1-hour incubation with an avidin-biotin complex (ABC) reagent. Sections were then incubated for 10 minutes in 0.5% biotinylated tyramine 1% H₂O₂ solution in 0.01 M PBS. They were reincubated[1] in the ABC reagent for 30 minutes. The stain was developed in diaminobenzidine and H₂O₂ and enhanced by nickel chloride in PBS. The sections were rinsed, dehydrated, mounted on a coverslip, and examined under the light microscope. Sections from uninjured control cases were processed using the same protocol.

Immunostaining for Glial Fibrillary Acidic Protein, CNPase, CD45, and CD68

Immunohistochemical techniques were used to detect the following antigens: glial fibrillary acidic protein (GFAP), 2', 3'-cyclic nucleotide 3'-phosphohydrolase (CNPase), and CD45/CD68. These antigens perform the following functions: GFAP is an astrocyte marker; CNPase is a myelin protein in the central nervous system and has been shown to be specific for oligodendrocytes;[45] and CD45 and CD68 were used to study activated microglia and macrophages.

Tissue sections were deparaffinized and endogenous peroxidase activity was blocked with 0.3% H₂O₂ in 100% methanol. Sections were incubated with either 0.3% Triton X-100 in 0.1 M PBS (GFAP) or with Tris

(pH 7.6) containing 10% normal goat serum. The sections were incubated overnight at room temperature with the following monoclonal antibodies: GFAP 1:200, CD45 1:100, CD68 1:100, and CNPase 1:800. This was followed by sequential incubation with biotinylated secondary antibody, ABC with horseradish peroxidase, 3,3'-diaminobenzidine, and H₂O₂. The slides were then counterstained with 2% cresyl violet, dehydrated, and mounted. Omission of the primary antibody served as a negative control.

Sources of Supplies and Equipment

The proteinase K and Hoechst 33342 dye were purchased from Sigma Chemical Co., St. Louis, MO. The apoptosis in situ kit was acquired from Chemicon International, Inc., Temecula, CA. The Axiophot fluorescent microscope was obtained from Zeiss, Inc., Oberkochen, Germany. The primary antibody CM-1 was a generous gift from IDUN Pharmaceuticals, Inc., La Jolla, CA. The biotinylated secondary antibody and ABC reagent (Vecta-stain) were acquired from Vector Laboratories, Burlingame, CA. The monoclonal antibodies GFAP, CD45, and CD68 were purchased from Dako Corp., Carpinteria, CA, and the CNPase from Sternberger Monoclonals, Inc., Baltimore, MD.

RESULTS

Clinical Data

The mean age of the 15 patients with SCIs (Table 1) was 49 years (range 16-80 years) and the mean age of the five control patients was 55 years (range 33-77 years). The principal causes of death in the patients with SCIs were pulmonary embolism (six patients), pneumonia (six patients), hemothorax with cardiac arrest in one, and an unknown cause in two patients. The causes of death for the control patients were cardiovascular disease in two and a motor vehicle accident (without head injury or SCI) in three. Only two patients with SCI (Cases 4 and 5) received methylprednisolone according to the National Acute Spinal Cord Injury Study, Phase II protocol.[8]

TABLE 1
SUMMARY OF THE CLINICAL DATA OF THE 15 PATIENTS WITH SCI*

| Case No. | Survival Time | Age (yrs), Sex | Injury Level | Cause of Injury | Neurological Status | Classification of Injury | Histopathological Findings at Lesion Epicenter | Presence & Location of Wallerian Degeneration |
|----------|---------------|----------------|--------------|-----------------|---------------------|--------------------------|--|---|
| 1 | 3 hrs | 72, M | T-6 | fall | complete | massive compression | maceration & hemorrhagic components | no wallerian degeneration |
| 2 | 3 days | 67, M | C-6 | fall | incomplete | solid cord | minor increase in interstitial spaces | subtle, above |
| 3 | 6 days | 74, M | C6-7 | MVA | complete | massive compression | all neural tissue damaged at epicenter | mild, above |
| †4 | 8 days | 20, F | C7-8 | GSW | complete | laceration | subtotal destruction of neural tissue at epicenter | moderate, above & below |
| †5 | 10 days | 22, M | C-7 | diving | incomplete | contusion | macerated tissue & phagocytic response at epicenter | mild, asymmetric; above & below |
| 6 | 12 days | 59, M | C-6 | MVA | complete | contusion | major loss of neural tissue at epicenter | severe, above & below |
| 7 | 12 days | 16, F | T-11 | GSW | complete | laceration | all neural tissue damaged at epicenter | very subtle, above & below |
| 8 | 12 days | 19, M | L-1 | GSW | complete | contusion | macerated tissue at epicenter; vascular infarction proximal to epicenter | severe, up to C-3 & below |
| 9 | 15 days | 38, M | T-5 | GSW | complete | laceration | spinal cord transected at T-5; necrotic tissue at T-4 w/invasion of macrophages | moderate, above & below |
| 10 | 16 days | 43, M | C5-6 | fall | complete | contusion | large blood-filled cavities w/m acrophage invasion at epicenter; preserved axon/m yelin units in extreme periphery of most of cord | mild |
| 11 | 16 days | 80, M | C-6 | fall | complete | contusion | large destruction of cord tissue w/m acrophages & hemorrhage | mild, more present above than below |
| 12 | 17 days | 70, M | C8 | MVA | complete | contusion | loss of neural tissue at epicenter | moderate, above & below |
| 13 | 17 days | 17, F | C6-7 | MVA | complete | contusion | macerated tissue in ventral & central portion of cord at epicenter | moderate; more present above than below |
| 14 | 45 days | 67, M | C5-7 | fall | complete | contusion | large destruction of cord tissue at epicenter | moderate, above & below |
| 15 | 60 days | 68, F | T-5 | fall | incomplete | contusion | loss of motor neurons at epicenter & diffuse axonal injury throughout dorsal columns & lateral & ventral corticospinal tracts | severe in dorsal |

* GSW = gunshot wound; MVA = motor vehicle accident.

† Received methylprednisolone according to the National Acute Spinal Cord Injury Study Phase II protocol.

Ten patients suffered a cervical and four a thoracic SCI, and one case consisted of a conus medullaris injury. Twelve patients presented with a complete motor and sensory loss below the level of their injury, whereas three experienced incomplete loss. The cause of injury was variable and included falls (six patients), motor vehicle accidents (four patients), gunshot wounds (four patients), and a diving accident (one patient).

Histological Data

We analyzed cross-sections of the lesion epicenter and rostral and caudal levels in tissue obtained in 15

patients who died between 3 hours and 60 days after their SCI. According to the classification established by Bunge, et al.,[9] nine patients presented with a contusion/cavity lesion, two with a massive compression, three with a laceration lesion, and one with a solid spinal cord syndrome.

All patients except the one in Case 2 showed significant destruction of the spinal cord parenchyma at the epicenter of the injury. Signs of wallerian degeneration in the white matter occurred as early as Day 3 postinjury and thereafter spread rostral and caudal to the lesion, with more advanced degeneration of the ascending tracts. In one patient (Case 8), the contusion was associated with a vascular infarction proximal to the epicenter and a pattern of obvious wallerian degeneration.

Morphological Appearance of Apoptotic Cells

Apoptotic nuclei were found in 14 of the 15 cases on hematoxylin and eosin- and cresyl violet-stained sections (Fig. 1A-C). Cells containing apoptotic nuclei exhibited evidence of cytoplasmic shrinkage. The nuclei themselves demonstrated chromatin condensation or aggregation into small and dark nuclear fragments. Staining with Hoechst 33342 revealed typically small and bright fragmented nuclei (Fig. 1D). No apoptotic bodies were detected on cresyl violet-stained sections from the five uninjured control patients.




Fig. 1. Photomicrographs showing apoptotic nuclei (arrowheads) within the traumatized human spinal cord stained with cresyl violet (A and B), H & E (C), and Hoechst 33342 (D). Apoptotic nuclei appear as condensed, clumped fragments. Bar = 20 μ m.

The in situ TUNEL technique (Fig. 2A) combined with propidium iodide (Fig. 2B) also demonstrated apoptotic TUNEL-positive nuclei as double-stained (yellow), fragmented nuclei (Fig. 2C) among numerous propidium iodide-positive cells. The location and quantity of apoptotic nuclei observed using this technique correlated with the number of apoptotic nuclei observed with hematoxylin and eosin- and cresyl violet-stained sections (paired t-test, $p = 0.16$; correlation coefficient 0.83).




Fig. 2. Photomicrographs showing TUNEL-labeled cells in the spinal cord at the epicenter level. Cross-sections of the spinal cord demonstrate a single TUNEL-positive labeled nucleus that

appears small and fragmented (A and B, arrowhead), among numerous normal nuclei counterstained by propidium iodide nuclear dye (B). On double exposure (C), the apoptotic cell is yellow (arrowhead), whereas the normal nuclei remain red. Bar = 50 μ m.

The presence of apoptotic cells was also demonstrated in sections immunostained with the CM-1 antibody. Most positive nuclei were dark and shrunken and contained condensed, clumped chromatin (Fig. 3A and B). Relatively more apoptotic cells were detected after CM-1 antibody staining compared with cresyl violet staining. Because cresyl violet staining was used to detect apoptotic bodies and CPP-32-positive cells did not necessarily contain these bodies, the implication is that immunostaining for CPP-32 activation detects apoptosis at an earlier stage. Staining with CPP-32 was also negative in Case 10, in which no apoptotic cells were shown in cresyl violet-stained sections. Staining with CPP-32 showed one to two positive cells per section in tissue obtained in one control patient (73 years old, died of cardiovascular disease), whereas tissue from the four other uninjured control patients was negative. Other potential explanations for the few apoptotic cells seen in tissue obtained in the one positive control case are the patient's advanced age and associated vascular disease.




Fig. 3. Photomicrographs showing CM-1 immunostaining of the dorsal columns at low (A) and high magnification (B) demonstrating a number of dark and shrunken cells (arrows) containing condensed and clumped chromatin. The staining for processed CPP-32 is evident within the nucleus (B). Bar = 200 μ m (A), 10 μ m (B).

Temporal and Spatial Distribution of Apoptotic Cells

Apoptotic cells were seen between 3 hours and 2 months postinjury. Although too few cases were analyzed to allow a correlation between the time after SCI and the number of apoptotic cells, most of these cells were seen in tissue obtained in patients who died between 3 days and 3 weeks after the SCI. Incomplete neurological status was associated with fewer apoptotic bodies (Cases 2, 5, and 15). When ischemia was associated with the primary injury, as in Case 8, a large number of apoptotic nuclei were observed throughout the levels studied.

Most apoptotic cells were randomly distributed in the rim of surviving tissue around the epicenter of the SCI and within the adjacent white matter (Table 2), and none was identified in the gray matter.

TABLE 2
DISTRIBUTION AND QUANTIFICATION OF APOPTOTIC CELLS PER SECTION*

| Case No. | Injury Level | Apoptotic Cells | Epicenter Level | 1-3 Levels Above Epicenter | 1-3 Levels Below Epicenter |
|----------|--------------|-----------------|-------------------------|---|--|
| 1 | T-6 | yes | no viable tissue | normal tissue (1-15) T-5; no apoptotic cells above T-5 | normal tissue; no apoptotic cells |
| 2 | C-6 | yes | edges of lesion (1-15) | dorsal columns (1-15) | ventral CST, lat CST (1-15); no apoptotic cells below C-8 |
| 3 | C6-7 | yes | no viable tissue | dorsal columns (15-30) | at edges of central cavity (1-15) |
| 4 | C7-8 | yes | edges of lesion (15-30) | dorsal columns (fx gracilis) (1-15) | ventral CST (T-1), (1-15); no apoptotic cells below T-2 |
| 5 | C-7 | yes | edges of cavity (1-15) | no apoptotic cells from C5-7 | dispersed at C-8 (1-15); no apoptotic cells at T-1 & below |
| 6 | C-6 | yes | edges of lesion (1-15) | dorsal columns, spinocerebellar tracts (15-30) | ventral CST (1-15) |
| 7 | T-11 | yes | edges of lesion (1-15) | dorsal columns (1-15) | dispersed T12-L1 (1-15); no apoptotic cells below L-2 |
| 8 | L-1 | yes | no viable tissue | dorsal columns (T-11) & a few cells in CST & spinocerebellar tracts (30-45) | ventral CST L3-5 (15-30) |
| 9 | T-5 | yes | no viable tissue | spinothalamic tract (T-3) (1-15) | no apoptotic cells T4-8 |
| 10 | C5-6 | no | — | — | — |
| 11 | C-6 | yes | edges of lesion (15-30) | dorsal columns (fx gracilis); spinothalamic tracts (1-15) | ventral CST (15-30) |
| 12 | C-8 | yes | edges of lesion (15-30) | dorsal columns & spinocerebellar tracts (15-30) | no apoptotic cells at T-1 & below |
| 13 | C6-7 | yes | edges of lesion (30-45) | dorsal columns & spinothalamic tracts (15-30) | ventral CST & lat CST (15-30) |
| 14 | C5-7 | yes | edges of lesion (1-15) | dorsal columns (1-15) | ventral CST & lat CST (1-15) |
| 15 | T-5 | yes | edges of lesion (1-15) | dorsal columns (1-15); no apoptotic cells above T-3 | ventral CST (1-15) |

* Numbers in parentheses represent the stratification of cell counts per section. Abbreviations: CST = corticospinal tract; fx = funiculus; — = not applicable.

Apoptotic cells were seen in areas of wallerian degeneration in the white matter above and below the epicenter. Rostral to the lesion epicenter, apoptosis was associated with axonal degeneration in ascending tracts, especially the fasciculus gracilis, the spinoreticular, the spinothalamic, and the spinocerebellar tracts. Degeneration and apoptosis were absent in the regions containing descending motor pathways. Apoptosis was associated with the degenerating axons in the descending tracts caudal to the lesion, especially the ventral corticospinal, reticulospinal, and vestibulospinal tracts; it was less prevalent in the lateral corticospinal or rubrospinal tracts, and no apoptotic cells were seen in the caudal ascending tracts. Apoptotic cells were seen in much larger numbers in ascending than in descending tracts, and wallerian degeneration was present earlier in the ascending tracts than in the descending tracts. There appeared to be a good correlation between apoptosis and wallerian degeneration. A schematic diagram (Fig. 4) demonstrates the spatial distribution of apoptotic cells at the SCI epicenter as well as above and below the lesion in the spinal cord of the patient in Case 13, who died 17 days postinjury.




Fig. 4. Schematic diagram demonstrating the spatial distribution of apoptotic cells in the spinal cord of the patient in Case 13, who died 17 days postinjury. The apoptotic bodies were identified on cresyl violet-stained sections and are represented as either filled circles at the epicenter level, empty circles above, or filled triangles below the lesion.

Apoptotic Cell Type

To identify the type of cells undergoing apoptosis, different antibodies directed against astrocytes (GFAP), oligodendrocytes (CNPase), and macrophages or activated microglia markers (CD45, CD68) were assayed. Apoptotic bodies were not seen in astrocytes (data not shown). Macrophages or activated microglia were seen engulfing fragments of apoptotic cells or with apoptotic bodies inside the cytoplasm or in proximity to such bodies unstained with microglia markers (Fig. 5).




Fig. 5. Photomicrographs showing oligodendrocytes immunostained with CNPase and nuclei counterstained with cresyl violet. Normal oligodendrocytes are seen (A), as well as multiple apoptotic oligodendrocytes (arrows) (B and C). Bar = 50 μ m.

Immunostaining with CNPase demonstrated that apoptotic cells (identified using cresyl violet counterstain) were present within oligodendrocytes adjacent to myelin sheaths in degenerating white matter tracts (Fig. 6).




Fig. 6. Photomicrographs showing activated microglia immunostained with CD68 before the section was counterstained with cresyl violet to demonstrate apoptotic bodies. Cells that did not stain with the activated microglia marker (A, arrow) as well as CD68-positive cells ingesting apoptotic bodies (B, arrow) were observed. Bar = 50 μ m.

DISCUSSION

Apoptosis is a form of physiological cell death, also defined as programmed cell death, in which cells die and are engulfed by phagocytes without discharging cytosolic contents into the extracellular space and without initiating an inflammatory reaction.[10] The cell surface membrane begins to bleb and express prophagocytic signals, the cell shrinks and severs contact with its neighbors, chromatin becomes condensed and cleared, and eventually the whole cell fragments into membrane-bound vesicles that are rapidly ingested by neighboring cells. The apoptotic process can be rapid when compared with necrotic cell death, and the debris is removed with similar swiftness.[27,37] Because the process is rapid, quantification of the number of apoptotic cells on any given cross-section underestimates the extent to which apoptosis contributes to the death of cells at the injury site.[52]

The genetic control and the biochemical markers of apoptotic cell death were initially elucidated in the roundworm **Caenorhabditis elegans**, and **CED 3** was identified as a gene encoding a protein involved in programmed cell death in this maturing roundworm.[30] The mammalian homologs of cell death mechanisms consist of the CED 3/interleukin-1-beta-converting enzyme (ICE) family of cysteine proteases (caspases),[17,38,40] in which the prototype is the ICE. The mammalian caspase family is composed of at least 10 known members.[2] One of these is CPP-32 (Yama, apopain), which has been definitively implicated in apoptosis.[16,26] The essential role of caspases in vertebrate apoptosis is consistent with their activity as the principal effectors of apoptosis through their proteolytic action on specific targets. One of the final effectors of cell death is activation of endonucleases that induce fragmentation of nuclear DNA into 185-bp fragments.[30] In a number of reports caspases have been implicated as important during apoptosis of neurons and astrocytes, and it has been suggested that CPP-32 was the principal effector in the apoptotic pathway.[4,33] Moreover, CPP-32 activation was never observed in necrotic cell death.[4,26] Hisahara, et al.,[26] demonstrated that caspase-1 (ICE) and caspase-3 (CPP-32) were expressed in oligodendrocytes and that their inhibition prevented apoptotic cell death.

Secondary injury processes are believed to be an important, remediable component of SCI.[8,49] Many of the basic research advances that have reached the clinical arena focus on the prevention of these secondary injury mechanisms.[21,55] Apoptotic cell death has been recognized for many years; however, this process has now

gained increasing attention in the basic science literature as a mechanism by which cells die in a number of neurological diseases.[47] Apoptotic cell death appears to be yet another mechanism in which cells may die in a delayed fashion after injury, that is, a secondary injury mechanism.

There is evidence that apoptotic cell death contributes to tissue damage, and prevention of this process results in neurological recovery after SCI[36] and brain injury in rats.[54] Data presented here indicate for the first time that apoptosis is associated with the tissue damage observed after human SCI. Our determination of apoptosis relied on multiple criteria: morphological staining (cresyl violet, hematoxylin and eosin), nuclear chromatin staining with Hoechst 33342 dye, and the TUNEL test, all of which have been widely used for assessment of apoptosis. These results were confirmed using immunostaining with the CM-1 antibody that is specific for the processed form of CPP-32 (A Srinivasan, et al., unpublished data). Caspase-3 is required for DNA fragmentation and the morphological changes associated with apoptosis.[30]

Crowe, et al.,[12] presented the first evidence for the presence of apoptosis in SCIs in the rat. Li, et al.,[35] demonstrated that compression trauma to the spinal cord was associated with apoptosis of glial cells preferentially located in degenerating longitudinal tracts of the white matter. The apoptotic cells were most likely oligodendrocytes, a conclusion based on morphological data and negative GFAP staining. Further studies demonstrated the occurrence of apoptosis in SCI in rats and monkeys and showed that oligodendrocytes were the major cell population undergoing apoptosis based on immunohistochemical analysis.[11,35] Apoptosis of oligodendrocytes was seen in areas of wallerian degeneration and was detected from 24 hours to 3 weeks postinjury.[11,12] Liu, et al.,[36] also observed a burst of neuronal and glial apoptosis in gray and white matter at the lesion site within the first 24 hours postinjury and a delayed wave of oligodendrocyte apoptosis in distant white matter several days later.

In our study, the lesion epicenter demonstrated the presence of multifocal hemorrhages and necrotic tissue involving the central gray matter and the contiguous white matter. Apoptotic cells were identified surrounding the lesion epicenter. As early wallerian degeneration occurred in the white matter tracts, a second phase of apoptotic cells appeared and these were positive for an oligodendrocyte marker (CNPase). Oligodendrocyte apoptosis was clearly associated with wallerian degeneration and was more obvious in ascending than in descending tracts. This corresponds to the pattern of progression of wallerian degeneration in which the ascending tracts show signs of degeneration before the descending tracts.[9]

We found no relationship between the average number of apoptotic bodies and time from injury because the injury mechanism and severity were different in each case. Nonetheless, it seemed that apoptosis was less severe in patients with incomplete neurological injuries. Liu, et al.,[36] demonstrated that after rat SCI, apoptotic glial cells were more abundant above than below the site of compression and that apoptotic cells were more numerous after moderate and severe injury compared with mild compression. We found no evidence of apoptosis within the spinal cord neurons. This indicates that any neuronal loss was the result of necrosis rather than apoptosis or that it occurred at an early stage before we could detect it. Tissue in only one of our cases was examined within 24 hours of death. Li, et al.,[35] demonstrated that neuronal apoptosis was complete within the first 24 hours, whereas Liu and colleagues[36] saw no evidence of apoptosis in the spinal cord neurons at 4 hours or 1, 4, and 9 days after compression trauma. We suspect that activated microglia (macrophages) clear apoptotic bodies, as has been observed by others,[13,14,48,51] but may also be partly responsible for the induction of apoptosis by secreting cytotoxic substances such as cytokines (tumor necrosis factor-alpha and nitric oxide).[53] Other investigators have also demonstrated that microglia can undergo apoptosis following damage to the nervous system.[20,42]

The mechanisms responsible for oligodendrocyte apoptosis remain unclear. It may occur as a result of loss of axonally derived survival signals (wallerian degeneration)[5] and/or as a result of evolving adverse changes

in the cellular milieu[13] resulting in axonal demyelination. If these axons are in continuity across the injury site, electrical conduction will be impaired through the axon. Recently, the presence of demyelinated axons around the epicenter of SCIs has received attention recently.[7,8] One therapeutic strategy for SCIs relies on the use of the drug 4-amino pyridine (a potassium channel blocker) to enhance axonal conduction through areas of demyelination.[23] Thus, prevention of axonal demyelination after SCI by the reduction of apoptotic oligodendrocyte cell death may result in an overall reduction of partially injured axons.

The contribution of CPP-32 activity and apoptosis to neuronal cell death after traumatic brain injury[54] and experimental transient ischemia[24,41] has been reported. In both injury paradigms, the use of caspase inhibitors not only reduced the extent of apoptosis, but also resulted in functional behavioral improvement in the animals. In that regard, therapeutic interventions aimed at blocking apoptosis may be useful in reducing tissue damage after SCI and ultimately in improving functional outcomes. Liu, et al.,[36] reported that intraperitoneal injections of cycloheximide, a protein synthesis inhibitor, improved behavioral outcomes after spinal cord contusion injury in rats. Partial inhibition of protein synthesis can induce the production of **Bcl-2**,[28] an antiapoptotic human protooncogene important in cell survival that was shown to be upregulated in injured axons of the white matter following compression injury of the spinal cord.[18,35] Hisahara, et al.,[27] demonstrated that caspases were involved in tumor necrosis factor-mediated cell death of oligodendrocytes and that inhibition of these proteases can prevent apoptosis. Milligan, et al.,[39] identified peptide inhibitors of the ICE protease family that arrest programmed cell death of motor neurons in vivo and in vitro. In that regard, it would be useful to test drugs that inhibit caspases in the treatment of SCI.

CONCLUSIONS

This work demonstrates for the first time that apoptotic cell death is observed from 3 hours to 8 weeks after traumatic human SCIs. Apoptosis occurs around the lesion epicenter as well as within areas of wallerian degeneration in both ascending and descending white matter tracts. Oligodendrocytes were definitely implicated as cells undergoing apoptosis on sections of injured spinal cord in which immunohistochemical markers were used. Apoptosis after human SCI appears to be dependent on activation of CPP-32. Inhibition of this process may have potential therapeutic benefits for reducing tissue damage and improving the outcome after SCI.

Acknowledgments

We are grateful to Tesha Monteith for her technical assistance and to Dr. Alexander Marcillo for his assistance in preparing the manuscript. We also thank Drs. Jacqueline Bresnahan and Hans Lassmann for their helpful advice.

References

1. Adams JC: Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. **J Histochem Cytochem** **40**:1457-1463, 1992
2. Alnemri ES, Livingston DJ, Nicholson DW, et al: Human ICE/CED-3 protease nomenclature. **Cell** **87**:171, 1996 (Letter)
3. Arends MJ, Wyllie AH: Apoptosis: mechanisms and roles in pathology. **Int Rev Exp Pathol** **32**:223-254, 1991
4. Armstrong RC, Aja TJ, Hoang KD, et al: Activation of the CED3/ICE-related protease CPP32 in cerebellar granule neurons undergoing apoptosis but not necrosis. **J Neurosci** **17**:553-562, 1997

5. Barres BA, Jacobson MD, Schmid R: Does oligodendrocyte survival depend on axons? **Curr Biol** **3**:489-497, 1993
6. Bauer J, Wekerle H, Lassmann H: Apoptosis in brain-specific autoimmune disease. **Curr Opin Immunol** **7**:839-843, 1995
7. Blight AR: Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. **Brain Res Bull** **22**:47-52, 1989
8. Bracken MB, Shepard MJ, Collins WF, et al: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second National Acute Spinal Cord Injury Study. **N Engl J Med** **322**:1405-1411, 1990
9. Bunge RP, Puckett WR, Becerra JL, et al: Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. **Adv Neurol** **59**:75-89, 1993
10. Cohen JJ: Apoptosis. **Immunol Today** **14**:126-130, 1993
11. Crowe MJ, Bresnahan JC, Shuman SL: Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. **Nature Med** **3**:73-76, 1997
12. Crowe MJ, Shuman SL, Masters JN, et al: Morphological evidence suggesting apoptotic nuclei in spinal cord injury. **Soc Neurosci Abstr** **21**:232, 1995 (Abstract)
13. Dusart I, Schwab ME: Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. **Eur J Neurosci** **6**:712-724, 1994
14. Duvall E, Wyllie AH, Morris RG: Macrophage recognition of cells undergoing programmed cell death (apoptosis). **Immunology** **56**:351-358, 1985
15. Ellis RE, Yvan J, Horvitz HR: Mechanisms and functions of cell death. **Annu Rev Cell Biol** **7**:663-698, 1991
16. Enari M, Talanian RV, Wong WW, et al: Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. **Nature** **380**:723-726, 1996 (Letter)
17. Fraser A, Evan G: A license to kill. **Cell** **85**:781-784, 1996
18. Furukawa K, Estus S, Fu WM, et al: Neuroprotective action of cycloheximide involves induction of Bcl-2 and antioxidant pathways. **J Cell Biol** **136**:1137-1149, 1997
19. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. **J Cell Biol** **119**:493-501, 1992
20. Gehrman J, Banati RB: Microglial turnover in the injured CNS: activated microglia undergo delayed DNA fragmentation following peripheral nerve injury. **J Neuropathol Exp Neurol** **54**:680-688, 1995
21. Hall ED, Yonkers PA, Andrus PK, et al: Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. **J Neurotrauma** **9** (Suppl):S425-S442, 1992
22. Hamburger V: Cell death in the development of the lateral motor column of the chick embryo. **J Comp Neurol** **160**:535-546, 1975

23. Hansebout RR, Blight AR, Fawcett S, et al: 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. **J Neurotrauma** **10**:1-18, 1993
24. Hara H, Friedlander RM, Gagliardini V, et al: Inhibition of interleukin 1-beta converting enzyme family proteases reduce ischemic and excitotoxic neuronal damage. **Proc Natl Acad Sci USA** **94**:2007-2012, 1997
25. Henderson CE: Programmed cell death in the developing nervous system. **Neuron** **17**:579-585, 1997
26. Hisahara S, Shoji S, Okano H, et al: ICE/ CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. **J Neurochem** **69**:10-20, 1997
27. Hockenberry D: Defining apoptosis. **Am J Pathol** **146**:16-19, 1995
28. Hockenberry DM, Oltvai ZN, Yin XM, et al: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. **Cell** **75**:241-251, 1993
29. Horwitz HR, Ellis HM, Sternberg DW: Programmed cell death in nematode development. **Neurosci Comment** **1**:56-65, 1982
30. Jänicke RU, Sprengart ML, Wati MR, et al: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. **J Biol Chem** **273**:9357-9360, 1997
31. Kane AB: Redefining cell death. **Am J Pathol** **146**:1-2, 1995
32. Katoh K, Ikata T, Katoh S, et al: Induction and its spread of apoptosis in rat spinal cord after mechanical trauma. **Neurosci Lett** **216**:9-12, 1996
33. Keane RW, Srinivasan A, Foster LM, et al: Activation of CPP32 during apoptosis of neurons and astrocytes. **J Neurosci Res** **48**:168-180, 1997
34. Kuida K, Zheng TS, Na S, et al: Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. **Nature** **384**:368-372, 1996
35. Li GI, Brodin G, Farooque M, et al: Apoptosis and expression of Bcl-2 after compression trauma to rat spinal cord. **J Neuropathol Exp Neurol** **55**:280-289, 1996
36. Liu XZ, Xu XM, Hu R, et al: Neuronal and glial apoptosis after traumatic spinal cord injury. **J Neurosci** **17**:5395-5406, 1997
37. Majno G, Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death. **Am J Pathol** **146**:3-15, 1995
38. Martin SJ, Green DR: Protease activation during apoptosis: death by a thousand cuts. **Cell** **82**:349-352, 1995
39. Milligan CE, Prevette D, Yaginuma H, et al: Peptide inhibitors of the ICE protease family arrest programmed cell death of motoneurons in vivo and in vitro. **Neuron** **15**:385-393, 1995
40. Nagata S: Apoptosis by death factor. **Cell** **88**:355-365, 1997
41. Namura S, Zhu J, Fink K, et al: Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. **J Neurosci** **18**:3659-3668, 1998
42. Nguyen KB, McCombe PA, Pender MP: Macrophage apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. **J Autoimmun** **17**:145-152, 1994

43. Nicotera P, Ankarcrona M, Bonfoco E, et al: Neuronal necrosis and apoptosis: two distinct events induced by exposure to glutamate or oxidative stress. **Adv Neurol** **72**:95-101, 1997
 44. Pender MP, Nguyen KB, McCombe PA, et al: Apoptosis in the nervous system in experimental allergic encephalomyelitis. **J Neurol Sci** **104**:81-87, 1991
 45. Prineas JW, Kwon EE, Goldenberg PZ, et al: Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. **Lab Invest** **61**:489-503, 1989
 46. Rink A, Fung KM, Trojanowski JQ, et al: Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. **Am J Pathol** **147**:1575-1583, 1995
 47. Savitz SI, Rosenbaum DM: Apoptosis in neurological disease. **Neurosurgery** **42**:555-574, 1998
 48. Shuman SL, Bresnahan JC, Beattie NS: Apoptosis of microglia and oligodendrocytes after spinal cord injury in rats. **J Neurosci Res** **50**:798-808, 1997
 49. Tator CH, Fehlings MG: Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. **J Neurosurg** **75**:15-26, 1991
 50. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. **Science** **267**:1456-1462, 1995
 51. Vela JM, Dalmau I, González B, et al: The microglial reaction in spinal cords of jimpy mice is related to apoptotic oligodendrocytes. **Brain Res** **712**:134-142, 1996
 52. Weedon D, Searle J, Kerr JF: Apoptosis. Its nature and implications for dermatopathology. **Am J Dermatopathol** **1**:133-144, 1979
 53. Wood PL: Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. **Neurol Res** **17**:242-248, 1995
 54. Yakovlev AG, Knoblach SM, Fan L, et al: Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. **J Neurosci** **17**:7415-7424, 1997
 55. Young W: Secondary injury mechanisms in acute spinal cord injury. **J Emerg Med** **11 (Suppl 1)**:13-22, 1993
-

Manuscript received January 7, 1998.

Accepted in final form August 4, 1998.

Address for Dr. Emery: Hôpital Beaujon, Clichy, France.

Address reprint requests to: Allan D. O. Levi, M.D., The Miami Project to Cure Paralysis, 1600 NW 10th Avenue, R-48, Miami, Florida 33101. email:alevi@mednet.med.miami.edu.
